Diagnostic value and limitations of fluorine-18 fluorodeoxyglucose positron emission tomography for cartilaginous tumors of bone

Journal of Bone and Joint Surgery

Volumn 86, Issue 12, 2004, Pages 2677-2685

  Lee, Francis Young In ^a   Yu, John ^a   Chang, Seong Sil ^a   Fawwaz, Rashid ^a   Parisien, May V ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; RADIOISOTOPE;

ARTICLE; BENIGN TUMOR; BONE CANCER; BONE METABOLISM; BONE RADIOGRAPHY; BONE SCINTISCANNING; CANCER GRADING; CARTILAGE TUMOR; CHONDROSARCOMA; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HISTOPATHOLOGY; HUMAN; LUNG METASTASIS; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE DIAGNOSIS; TUMOR BIOPSY; TUMOR RECURRENCE; TUMOR VOLUME;

EID: 10344247117     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/00004623-200412000-00014     Document Type: Article

References (23)

1. Lee FY, Mankin HJ, Fondren G, Gebhardt MC, Springfield DS, Rosenberg AE, Jennings LC. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am. 1999;81:326-38.
2. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61-77.
3. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign versus malignant hepatic lesions with positron emission tomography. Arch Surg. 1998;133:510-6.
4. Delbeke D. Oncological applications of FDG PET imaging. J Nucl Med. 1999;40:1706-15.
5. Aoki J, Watanabe H, Shinozaki T, Tokunaga M, Inoue T, Endo K. FDG-PET in differential diagnosis and grading of chondrosarcomas. J Comput Assist Tomogr. 1999;23:603-8.
6. Kirkwood BR, Sterne JAC, editors. Essential medical statistics. 2nd ed. Malden, MA: Blackwell Science; 2003.
7. Gilman J, Myatt M. Epicalc 2000 software. Version 1.02. www.brixton-health.com
8. Cook GJ, Fogelman I, Malsey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308-14.
9. Dehdashtl F, Slegel BA, Griffeth LK, Fusselman MJ, Trask DD, McGuire AH, McGuire DJ. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18] fluoro-2-deoxy-D-glucose. Radiology. 1996;200:243-7.
10. Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig E, Sarkar MR, Diederichs CG, Schultheiss M, Kotzerke J, Reske SN. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? Eur J Nucl Med. 1999;26:599-605.
11. Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig E, Sarkar MR, Diederichs CG, Von Baer A, Kotzerke J, Reske SN. Grading of tumors and tumor-like lesions of bone: evaluation by FDG PET. J Nucl Med. 2000;41:1695-701.
12. Aoki J, Watanabe H, Shinozaki T, Takagishi K, Ishijima H, Oya N, Sato N, Inoue T, Endo K. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology. 2001;219:774-7.
13. Folpe AL, Lyles RH, Sprouse JT, Conrad EU 3rd, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000;6:1279-87.
14. D'Amico TA, Wong TZ, Harpole DH, Brown SD, Coleman RE. Impact of computed tomography-positron emission tomography fusion in staging patients with thoracic malignancies. Ann Thorac Surg. 2002;74:160-3.
15. Jerusalem G, Hustinx R, Beguin Y, Fillet G. PET scan imaging in oncology. Eur J Cancer. 2003;39:1525-34.
16. Chung JK, Chang YS, Lee YJ, Kim YJ, Jeong JM, Lee DS, Jang JJ, Lee MC. The effect of tumor size on F-18-labeled fluorodeoxyglucose and fluoroerythronitroimidazole uptake in a murine sarcoma model. Ann Nucl Med. 1999;13:303-8.
17. Jerusalem G, Hustinx R, Beguin Y, Fillet G. The value of positron emission tomography (PET) imaging in disease staging and therapy assessment. Ann Oncol. 2002;13 (Suppl 4):227-34.
18. Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T, Taniguchi M, Tonami H, Okimura T, Yamamoto I. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med. 1998;39:1016-20.
19. Rege SD, Hoh CK, Glaspy JA, Aberle DR, Dahlbom M, Razavi MK, Phelps ME, Hawkins RA. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer. 1993;72:82-90.
20. Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, Fillet G. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol. 2001;12:825-30.
21. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology. 1996;199:751-6.
22. Cook GJ, Fogelman I, Malsey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308-14.
23. Coleman RE. PET in lung cancer. J Nucl Med. 1999;40:814-20.